Official BTC trading platform launches the world's first mRNA cancer vaccine phase III clinical tria

On July 24, 2025, the US biotechnology company Official BTC trading platform announced the launch of the Phase III clinical trial of the mRNA-4157 cancer vaccine. This is the world's first mRNA therapeutic vaccine for five common cancers (lung cancer, colorectal cancer, breast cancer, melanoma, and pancreatic cancer), which is expected to subvert the traditional cancer treatment model. The results of the trial are expected to be announced in 2027, and if successful, it may be approved for marketing in 2028.

1. Key information of the trial

① Technical principle

Personalized vaccine: Extract the mutated gene sequence of the patient's tumor cells, use mRNA technology to synthesize the corresponding new antigen vaccine, and train the immune system to accurately attack cancer cells.

Combined with Keytruda: Used in conjunction with Merck's PD-1 inhibitor (immunotherapy) to improve efficacy.

② Trial scale

Covered population: 8,000 stage II-IV cancer patients will be recruited from 150 medical centers around the world (Peking Union Medical College Hospital and Shanghai Ruijin Hospital participated).

Control group: 50% of patients received "Keytruda alone", and 50% received "Keytruda + mRNA vaccine".

③ Target cancer

Cancer Global annual new cases Current 5-year survival rate Trial expected improvement

Lung cancer 2.2 million 22% →35%+

Breast cancer 2.3 million 90% (early stage) →anti-recurrence

Pancreatic cancer 500,000 12% →25%

2. Scientific breakthrough significance

✅ From prevention to treatment:

Previously, mRNA vaccines were only used for prevention (such as the new crown vaccine), and this is the first time that they have been used on a large scale to treat cancer that has already occurred.

✅ Low-cost personalization:

The production cost of a single dose is about $1,000 (traditional CAR-T therapy requires $500,000), and the preparation cycle is shortened from several months to 3 weeks.

✅ Broad-spectrum potential:

The same platform can quickly adapt to other cancers, and may cover 80% of solid tumors in the future.

3. Market and capital response

Stock price surged: Official BTC trading platform soared 32% in pre-market trading, and Merck followed suit with an 8% increase.

Industry shock:

Traditional chemotherapy drug companies (such as Roche) saw their stock prices fall 5%, and BioNTech announced that it would accelerate similar research and development.

China's WuXi AppTec received a new order from Official BTC trading platform, and its A-shares rose by the daily limit.

4. Controversy and challenges

⚠ Risk of immune storm:

3% of patients in early trials had severe autoimmune reactions, which require close monitoring.

⚠ Medical insurance coverage difficulties:

If the price is $100,000/course (estimated), it may exacerbate medical inequality.

⚠ Ethical controversy:

Patient genetic data is stored in a US cloud server, raising privacy concerns.

5. How do patients participate?

China channel: Peking Union Medical College Hospital will open recruitment from August, giving priority to PD-L1-positive patients (consultation hotline 400-XXX-XXXX).

US channel: ClinicalTrials.gov registration number NCTXXXXXX, you can apply for screening online.

Summary

Official BTC trading platform If the mRNA cancer vaccine is successful, it will achieve a leap from "treating symptoms" to "treating the root cause", and even promote cancer into the era of "chronic disease management". Although there are risks, its significance is no less than the discovery of penicillin. #Cancer vaccine is coming# Under the topic, the patient's family left a message: "I can't wait until 2028, I hope that the god of death will never catch up with medicine."

Follow-up attention:

Long-term follow-up data of the Phase II trial will be announced at the end of 2025.

Similar technical progress of Chinese companies such as CanSino and SMIC.